Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France; CHU Lille, Pôle de Psychiatrie, F-59000 Lille, France.
Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France; CHU Lille, Pôle de Psychiatrie, F-59000 Lille, France; Centre National de Ressources et de Résilience Lille-Paris (CN2R), Lille F-59000, France.
J Psychosom Res. 2023 Mar;166:111172. doi: 10.1016/j.jpsychores.2023.111172. Epub 2023 Jan 25.
Evidence shows that many patients with COVID-19 present persistent symptoms after the acute infection. Some patients may be at a high risk of developing Somatic Symptom Disorder (SSD), in which persistent symptoms are accompanied by excessive and disproportionate health-related thoughts, feelings and behaviors regarding these symptoms. This study assessed the frequency of persistent physical symptoms and SSD and their associated factors in patients with confirmed COVID-19.
We conducted a longitudinal retrospective study after the first two French lockdowns at the Lille University Hospital (France), including all patients with confirmed COVID-19. Persistent physical symptoms and excessive preoccupations for these symptoms were measured 8 to 10 months after the onset of COVID-19. The combination of the Patient Health Questionnaire-15 and the Somatic Symptom Disorder-B Criteria Scale was used to identify the individuals likely to present with SSD. Two linear regression models were performed to identify sociodemographic and medical risk factors of SSD.
Among the 377 patients with a laboratory-confirmed diagnosis, 220 (58.4%) completed the questionnaires. Sixty-five percent of the 220 included patients required hospitalization, 53.6% presented at least one persistent physical symptom and 10.4% were considered to present SSD. Female sex, older age, infection during the second wave and having probable PTSD were significantly associated with the severity of SSD and SSD was associated with a significantly higher healthcare use.
The identification of SSD should encourage clinicians to move beyond the artificial somatic/psychiatric dualism and contribute to a better alliance based on multi-disciplinary care.
有证据表明,许多 COVID-19 患者在急性感染后仍存在持续症状。一些患者可能存在躯体症状障碍(SSD)的高风险,其持续症状伴有对这些症状的过度和不成比例的健康相关想法、感受和行为。本研究评估了确诊 COVID-19 患者持续躯体症状和 SSD 的频率及其相关因素。
我们在法国里尔大学医院进行了首次两次法国封锁后的纵向回顾性研究,纳入了所有确诊 COVID-19 的患者。在 COVID-19 发病后 8 至 10 个月测量持续的躯体症状和对这些症状的过度关注。使用患者健康问卷-15 和躯体症状障碍-筛选标准量表组合来识别可能存在 SSD 的个体。进行了两个线性回归模型以确定 SSD 的社会人口学和医学风险因素。
在 377 例经实验室确诊的患者中,有 220 例(58.4%)完成了问卷调查。220 例纳入患者中 65%需要住院治疗,53.6%存在至少一种持续躯体症状,10.4%被认为存在 SSD。女性、年龄较大、第二波感染和可能患有创伤后应激障碍与 SSD 的严重程度显著相关,SSD 与更高的医疗保健使用显著相关。
SSD 的识别应鼓励临床医生超越人为的躯体/精神二元论,并有助于基于多学科护理的更好联盟。